Developments in the use of nanocapsules in oncology

Yurgel, Virgina Campello; Collares, Tiago; Seixas, Fabiana Kömmling

doi:10.1590/1414-431x20132643

Cited by 31 publications

(12 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vakilinezhad et al [22] described PLGA nanoparticles containing CUR and MTX with an initial burst release that was attributed to the drug dispersion into the superficial layers of these particles. In the present study, a typical core-shell structure was strategically planned to avoid this effect and to achieve a prolonged drug release for circumventing the administration of multiple doses per day of chemotherapy [42].…”

Section: In Vitro Drug Release Studymentioning

confidence: 99%

Co-Loaded Curcumin and Methotrexate Nanocapsules Enhance Cytotoxicity against Non-Small-Cell Lung Cancer Cells

et al. 2020

View full text Add to dashboard Cite

Background: As part of the efforts to find natural alternatives for cancer treatment and to overcome the barriers of cellular resistance to chemotherapeutic agents, polymeric nanocapsules containing curcumin and/or methotrexate were prepared by an interfacial deposition of preformed polymer method. Methods: Physicochemical properties, drug release experiments and in vitro cytotoxicity of these nanocapsules were performed against the Calu-3 lung cancer cell line. Results: The colloidal suspensions of nanocapsules showed suitable size (287 to 325 nm), negative charge (−33 to −41 mV) and high encapsulation efficiency (82.4 to 99.4%). Spherical particles at nanoscale dimensions were observed by scanning electron microscopy. X-ray diffraction analysis indicated that nanocapsules exhibited a non-crystalline pattern with a remarkable decrease of crystalline peaks of the raw materials. Fourier-transform infrared spectra demonstrated no chemical bond between the drug(s) and polymers. Drug release experiments evidenced a controlled release pattern with no burst effect for nanocapsules containing curcumin and/or methotrexate. The nanoformulation containing curcumin and methotrexate (NCUR/MTX-2) statistically decreased the cell viability of Calu-3. The fluorescence and morphological analyses presented a predominance of early apoptosis and late apoptosis as the main death mechanisms for Calu-3. Conclusions: Curcumin and methotrexate co-loaded nanocapsules can be further used as a novel therapeutic strategy for treating non-small-cell lung cancer.

show abstract

Section: In Vitro Drug Release Studymentioning

confidence: 99%

Co-Loaded Curcumin and Methotrexate Nanocapsules Enhance Cytotoxicity against Non-Small-Cell Lung Cancer Cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“…These features have made biodegradable polymeric nanocpasules (NCs) one of the most widely used. They can achieve high water insoluble drug loading, facilitate intratumoral distribution, and protect the active agent from premature degradation, allowing its sustained and controlled release . NCs exhibit a typical core–shell structure in which active molecules are confined to an oil‐core that is surrounded by a polymer membrane or coating .…”

Section: Introductionmentioning

confidence: 99%

“…intratumoral distribution, and protect the active agent from premature degradation, allowing its sustained and controlled release. [2][3][4] NCs exhibit a typical core-shell structure in which active molecules are confi ned to an oil-core that is surrounded by a polymer membrane or coating. [ 5 ] Curcumin, has shown a wide range of pharmacological activities and has attracted great interest due to the possibility of tumor growth inhibition via multiple mechanisms.…”

Section: Introductionmentioning

confidence: 99%

Passively Targeted Curcumin-Loaded PEGylated PLGA Nanocapsules for Colon Cancer Therapy In Vivo

Klippstein

Wang

El-Gogary

et al. 2015

Small

103

View full text Add to dashboard Cite

Clinical applications of curcumin for the treatment of cancer and other chronic diseases have been mainly hindered by its short biological half-life and poor water solubility. Nanotechnology-based drug delivery systems have the potential to enhance the efficacy of poorly soluble drugs for systemic delivery. This study proposes the use of poly(lactic-co-glycolic acid) (PLGA)-based polymeric oil-cored nanocapsules (NCs) for curcumin loading and delivery to colon cancer in mice after systemic injection. Formulations of different oil compositions are prepared and characterized for their curcumin loading, physico-chemical properties, and shelf-life stability. The results indicate that castor oil-cored PLGA-based NC achieves high drug loading efficiency (≈18% w(drug)/w(polymer)%) compared to previously reported NCs. Curcumin-loaded NCs internalize more efficiently in CT26 cells than the free drug, and exert therapeutic activity in vitro, leading to apoptosis and blocking the cell cycle. In addition, the formulated NC exhibits an extended blood circulation profile compared to the non-PEGylated NC, and accumulates in the subcutaneous CT26-tumors in mice, after systemic administration. The results are confirmed by optical and single photon emission computed tomography/computed tomography (SPECT/CT) imaging. In vivo growth delay studies are performed, and significantly smaller tumor volumes are achieved compared to empty NC injected animals. This study shows the great potential of the formulated NC for treating colon cancer.

show abstract

“…[15] However, cationic liposomes can be disadvantageous because of their potentially high cytotoxicity. [17,22] The use of neutral lipids has thus been investigated, and studies have demonstrated that they are more biocompatible and have superior pharmacokinetics when compared to their cationic counterparts. Entrapment efficiency of siRNA does decrease with neutral lipids, but modifications can be made to the neutral lipoplexes to increase entrapment efficiency.…”

Section: Lipoplexesmentioning

confidence: 99%

“…[25,30,31] Dendrimers are also similar to lipid-based vectors due to high cytotoxicity being associated with not only cationic lipid-based vectors but cationic dendrimers as well. [17,22,30] However, dendrimers can also be modified through PEGylation to not only increase the duration of its circulation in the blood but also to decrease its toxicity and increase its transfection efficacy. [32] The last/outer generation on the dendrimer (each concentric layer of a dendrimer is considered a generation) has a specific amount of functional groups that can be produced to ensure wanted interactions with appropriate tissues.…”

Section: Dendrimersmentioning

confidence: 99%

An Overview of Various Carriers for siRNA Delivery

Marquez¹,

Madu²,

Lü³

2018

Oncomedicine

View full text Add to dashboard Cite

RNA interference through the use of short interfering molecules known as short interfering RNA (siRNA) has the potential to greatly advance research in treatments for many diseases because it has the ability to silence the expression of specific genes by helping degrade target mRNA. However, challenges to siRNA delivery have made the development of safe and effective delivery systems paramount in siRNA research. Various types of delivery systems have been proposed and investigated for siRNA delivery and therapy. Although viral vectors have been established to be the most effective in delivering siRNA molecules, they also raise many concerns over biosafety, especially concerning immunogenicity. Therefore, many researchers have begun to investigate and study non-viral vectors. Non-viral vectors are studied because they are typically considered to be safer than viral vectors albeit less efficient as well. The three general non-viral vectors that have been studied for siRNA delivery are lipid-based, non-lipid organic-based, and non-lipid inorganic-based carriers. Within those general parameters of non-viral vector classification are subtypes that are each unique with their own characteristic benefits and downsides. Many of these carriers, as well as even naked siRNA, do have the potential to be modified so that siRNA delivery could be further enhanced with benefits such as greater stability and duration. Researchers still must be wary with alterations as to not interfere with siRNA function. Currently, widespread siRNA therapeutics are still out of reach, but as more advancements in siRNA research including research on their delivery mechanisms are established, the goal of integrating siRNA therapy into the treatment of a multitude of diseases becomes increasingly more of a possibility. Researchers are currently investigating how siRNA can be used to not just treat cancer but ocular and neurodegenerative diseases as well as many others. There are still many obstacles to face and overcome before siRNA therapy can be implemented into the treatment of many diseases, and more research must still be conducted concerning siRNA delivery systems. Many advancements pertaining to siRNA carriers have been made, and many more are likely on their way.

show abstract

Developments in the use of nanocapsules in oncology

Cited by 31 publications

References 88 publications

Co-Loaded Curcumin and Methotrexate Nanocapsules Enhance Cytotoxicity against Non-Small-Cell Lung Cancer Cells

Co-Loaded Curcumin and Methotrexate Nanocapsules Enhance Cytotoxicity against Non-Small-Cell Lung Cancer Cells

Passively Targeted Curcumin-Loaded PEGylated PLGA Nanocapsules for Colon Cancer Therapy In Vivo

An Overview of Various Carriers for siRNA Delivery

Contact Info

Product

Resources

About